New combo aims to reboot immune attack on tough head and neck cancers
NCT ID NCT04150900
First seen Mar 06, 2026 · Last updated Jun 15, 2026 · Updated 17 times
Summary
This study tests whether adding bavituximab to pembrolizumab can help the immune system fight advanced head and neck cancer that has stopped responding to standard immunotherapy. About 7 adults whose cancer worsened after prior treatment will receive the combination. The main goal is to see if tumors shrink or disappear.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Maryland Medical Center
Baltimore, Maryland, 21201, United States
Conditions
Explore the condition pages connected to this study.